Infographic: The Big Pharma Takeover of Medical Cannabis
Connect with us

Markets

The Big Pharma Takeover of Medical Cannabis

Published

on

INFO

The Big Pharma Takeover of Medical Cannabis

As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies.

Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry.

Who are “Big Pharma”?

The term refers to some of the largest pharmaceutical companies in the world, considered especially influential as a group. To give a sense of their sheer size, the market cap of the top 10 Big Pharma companies is $1.7 trillion—Johnson & Johnson being the largest, with a market capitalization of $374 billion.

So far, Big Pharma has watched the cannabis industry from the sidelines, deterred by regulatory concerns. What we are seeing now is the sleeping giant’s takeover slowly intensifying as more patents, partnerships, and sponsored clinical trials come to fruition.

Could Cannabis be Sold Over the Counter?

The cannabis plant has been used in medicine for 6,000 years. However, there is still considerable debate around the role it plays in healthcare today. There are currently almost 400 active and completed clinical trials worldwide surrounding cannabidiol (CBD), a type of cannabinoid that makes up 40% of the cannabis plant’s extract.

Cannabis relies on CBD’s therapeutic properties, and recent studies suggest it may be useful in combating a variety of health conditions, such as:

  • Epilepsy
  • Schizophrenia
  • Multiple sclerosis
  • Migraines
  • Arthritis
  • Cancer side effects

As of 2019, 33 states and the District of Columbia have legalized cannabis for medical use. Its potential for pain management has led some experts to recommend it as an alternative to addictive painkillers, with one study of 13 states showing opiate-related deaths decreasing by over 33% in the six years since medical cannabis was legalized.

As the industry evolves, data is becoming increasingly important in understanding the potential of cannabis—both as a viable medical treatment, and as a recreational product. The shift away from anecdotal evidence towards big data will inform future policies, and give rise to a new era of consumer education.

Big Pharma’s Foray into Cannabis

Further legalization of cannabis will challenge Big Pharma’s bottom line, and poach more than $4 billion from pharma sales annually. In fact, medical cannabis sales are projected to reach $5.9 billion in 2019, from an estimated 24 million patients.

Seven of Canada’s top 10 cannabis patent holders are major multinational pharmaceutical companies, a trend that is not unique to Canada.

Company Rank🇨🇦 Canadian PatentsCompany Rank🇺🇸 U.S. Patents
1. Novartis211. Abbvie59
2. Pfizer142. Sanofie39
3. GW Pharmaceuticals133. Merck35
4. Ericsson134. Bristol-Myers Squibb34
5. Merck115. GW Pharmaceuticals28
6. Solvay Pharmaceuticals76. Pfizer25
7. Kao Corporation77. Hebrew University of Jerusalem19
8. Ogeda SA78. Roche17
9. Sanofi69. University of Connecticut16
10. University of Connecticut610. U.S. Health and Human Services13

It comes as no surprise that many pharmaceutical giants have already formed strong partnerships with cannabis companies, such as Novartis and Tilray, who will develop and distribute medical cannabis together in legal jurisdictions around the world.

Data is the Missing Link

While the body of knowledge about the many uses of cannabis continue to grow, clinical evidence is key for widespread adoption.

Products backed by data will be a defining criteria for major companies to come into the market en masse. And ultimately, Big Pharma’s entry could accelerate public understanding and confidence in cannabis as a viable option for a range of ailments, and mark the next major milestone for the industry.

Click for Comments

Markets

Visualizing Ukraine’s Top Trading Partners and Products

This graphic visualizes Ukraine’s top international trading partners and the country’s most exported and imported products in 2020.

Published

on

ukraine international trade

Visualizing Ukraine’s Top Trading Partners and Products

This was originally posted on Elements. Sign up to the free mailing list to get beautiful visualizations on natural resource megatrends in your email every week.

International trade was equal to 65% of Ukraine’s GDP in 2020, totaling to $102.9 billion of goods exchanged with countries around the world.

In 2014, Russia’s annexation of Crimea contributed to a 30% year-over-year drop in Ukraine’s 2015 trade value ($75.6B). Now, Ukraine’s international trade has been irreversibly disrupted since Russia’s full-scale invasion on February 24th, 2022.

The current conflict continues to reshape geopolitical relations and international trade—and to give context to the situation, we’ve created this graphic using IMF and UN Comtrade data to showcase Ukraine’s largest trading partners and goods traded in 2020.

Ukraine’s Largest Trading Partners

Ukraine’s largest trading partner in 2020 was China, with the value of trade between the two countries reaching $15.3 billion, more than double the value of any other trading partner.

Germany ($7.4B), Poland ($7.4B), and Russia ($7.2B) were Ukraine’s next three largest trading partners, with the majority of Ukraine’s trade with these countries being imports.

CountryTrade with Ukraine (2020) Exports from Ukraine (%)Imports to Ukraine (%)
🇨🇳 China$15.3B46%54%
🇩🇪 Germany$7.4B28%72%
🇵🇱 Poland$7.4B45%55%
🇷🇺 Russia$7.2B37%63%
🇹🇷 Turkey$4.8B50%50%
🇧🇾 Belarus$4.2B32%68%
🇮🇹 Italy$4.1B48%52%
🇺🇸 U.S.$3.9B25%75%
🇮🇳 India$2.7B73%27%
🇳🇱 Netherlands$2.6B71%29%

Source: IMF

While most of Ukraine’s trade with top partners is made up of imports, trade with both India and the Netherlands (Ukraine’s ninth and tenth largest trading partners respectively) was more export driven, with exports holding a greater than 70% share of total trade value.

Ukraine’s Top Exports and Imports

Ukraine’s strong agricultural industry makes up a large share of the country’s exports in the form of cereals, animal and vegetable oils, and seed oils. These products made up nearly 35% of Ukraine’s exports in 2020, at a value of $17 billion collectively.

Goods Exported from Ukraine (2020)Dollar ValueShare of Exports
Cereals$9.4B19.1%
Iron and steel$7.7B15.6%
Animal or vegetable fats, oils, and other products$5.8B11.7%
Ores, slag, and ash$4.4B8.9%
Electrical machinery and equipment$2.6B5.2%
Other goods$19.4B39.5%

Source: UN Comtrade

The other two cornerstones of Ukraine’s industry and exports are iron ore and steel, along with refined electrical machinery, equipment, and other mechanical appliances. In 2020, exports of crude iron and steel along with their refined products made up $13 billion in value, making up more than a quarter of Ukraine’s exports.

Ukraine’s imports are primarily vehicles, machinery, and the fuels necessary to power these goods. With the country’s energy consumption outpacing domestic energy production, mineral fuels and oils are Ukraine’s top import in 2020 at $7.42 billion.

Goods Imported from Ukraine (2020)Dollar ValueShare of Imports
Mineral fuels, oil, and mineral products $7.4B13.8%
Boilers, machinery and mechanical appliances$6.3B11.7%
Vehicles other than railway or tramway rolling stock$5.5B10.2%
Electrical machinery and equipment$5.3B9.9%
Pharmaceutical products$2.5B4.7%
Other goods$26.6B49.7%

Source: UN Comtrade

Primarily importing from Belarus, Russia, and Germany, Ukraine’s need for energy fuels was greatly exacerbated by Russia’s annexation of the Crimean peninsula, which held 80% of Ukraine’s oil and natural gas deposits in the Black Sea.

Various kinds of machinery, vehicles, and electrical equipment are the next largest categories of goods imported, cumulatively making up 31% ($17.1B) of Ukraine’s imports.

Ukraine’s Shift Away from Russian Trade Dependence

Since its independence from the former USSR in 1991, Ukraine has steadily shifted towards Western trading partners, especially as conflicts with Russia escalated in the 2010s.

After years of negotiations, Ukraine’s Association Agreement with the EU in 2014 facilitated free trade between EU nations and Ukraine, reducing the country’s dependence on trade with Russia.

Ukraine is one of the most important economic centers of the former Soviet Union, and it had long been the breadbasket of the USSR thanks to its fertile chernozem soil and strong agricultural industry.

Trade value between Russia and Ukraine peaked in 2011 at $49.2 billion, and since then has fallen by 85% to $7.2 billion in 2020. During this time, European nations like Poland and Germany overtook Russia in terms of trade value with Ukraine, and in 2021 trade with the EU totaled to more than $58 billion.

War’s Effect on Ukraine’s Future Trading Partners

Russia’s invasion of Ukraine is rapidly reshaping both countries’ international relations and trading partners.

Four days into the recent conflict, Ukrainian President Zelenskyy filed for Ukraine’s special admission into the EU, which would further strengthen Ukraine’s trade with European Union members. Combining the likely breakdown of Ukrainian-Russian trade with China’s lack of condemnation of Russia’s actions, Ukraine’s trade seems likely to continue shifting towards the European Union and its Western allies.

While not exactly international trade, on February 26th the U.S. committed an additional $350 million in support to Ukraine, with American financial security assistance to Ukraine totaling $1 billion over the past year. Alongside the U.S., the EU recently committed €500 million in financial support, and multiple EU and non-EU nations are providing Ukraine with military aid.

Although it’s impossible to determine the results of this conflict and its effects on international trade, the countries supporting Ukraine’s defense today are likely to become the Ukraine’s top trading partners in the future.

Continue Reading

Green

Putting EV Valuations Into Perspective

EV valuations have exploded since 2020, dwarfing those of legacy automakers like Ford and Toyota. Gain further insight with this infographic.

Published

on

Putting EV Valuations Into Perspective

The global push for lower emissions has created a mania around pure-electric automakers. While Tesla leads the charge, institutional investors have also piled into many of its younger rivals.

For example, in 2019, Saudi Arabia’s sovereign wealth fund invested $1.3 billion into Lucid Motors. One year later, it was revealed that Amazon had a 20% stake (worth $3.8B) in Rivian.

To see how quickly EV valuations have ballooned, we’ve visualized the historical market capitalizations (market caps) of 10 prominent automakers.

Legacy vs Pure-Electric

The legacy group includes five top traditional automakers, while the EV group includes the five most valuable pure-electric automakers that are listed on an American exchange.

The following table lists the market caps of these companies at various dates. While XPeng and NIO are listed on the New York Stock Exchange, they do not currently sell cars in the U.S.

AutomakerType20102015202102/22/2022
🇺🇸 TeslaEV$3B$31B$1,061B$849B
🇯🇵 ToyotaLegacy$124B$191B$255B$256B
🇩🇪 Volkswagen GroupLegacy$59B$79B$129B$128B
🇩🇪 Mercedes-BenzLegacy$61B$94B$83B$89B
🇺🇸 FordLegacy$63B$57B$83B$69B
🇺🇸 General MotorsLegacy$55B$51B$85B$68B
🇺🇸 RivianEVN/AN/A$93B$55B
🇺🇸 LucidEVN/AN/A$63B$42B
🇨🇳 NIOEVN/AN/A$50B$35B
🇨🇳 XpengEVN/AN/A$41B$30B

Source: Companies Market Cap

At the end of 2021, Tesla and its four EV rivals were worth a combined $1.3 trillion. This was more than double of the legacy group, which was worth $635 billion. EV valuations have cooled since then, though Tesla is still the world’s most valuable automaker by a significant margin.

U.S. Sales in 2021

Comparing U.S. sales gives an interesting perspective on these companies’ relative scale. Once again, note that XPeng and NIO do not sell cars in America. We’ve provided figures for their home market (China) instead.

AutomakerU.S. Sales in 2021
General Motors2.3 million
Toyota2.2 million
Ford1.9 million
Volkswagen Group630,000
Tesla361,000 (est.)
Mercedes-Benz330,000
XPeng98,000 (China)
NIO91,000 (China)
Rivian920
Lucid 520 (est.)

Source: Good Car Bad Car

Impressively, Tesla has overtaken Mercedes in the U.S. to become one of the country’s top luxury brands.

The Long Road Ahead

To satisfy investor expectations, Rivian and Lucid will need to rapidly scale their production and sales. Failing to do so could lead to significant stock price volatility.

Investors should also note that both companies could experience similar challenges as Tesla, which Musk has referred to as “production hell”. Rivian has already pushed back deliveries of its first SUV, while Lucid customers have been notified of delays due to “fit and finish” issues.

Nevertheless, these young manufacturers are setting some serious goals. Rivian aims to produce one million cars annually by the year 2030, while Lucid is targeting a more conservative 49,000 cars in 2023.

Tesla Goes on the Defensive

Tesla is still the undisputed EV leader, but competition is rapidly heating up.

On one hand, legacy automakers have been investing heavily in EV development, and new models are coming en masse. The Volkswagen Group is the biggest threat, selling 453,000 EVs globally in 2021 (up 96% over 2020). For reference, Tesla reported global sales of 936,000 in 2021.

On the other hand, Tesla must also defend its market share from an onslaught of Chinese entrants. This includes XPeng and NIO, which appear to be on similar trajectories. Both firms were founded in 2014, both sold nearly 100,000 EVs in 2021, and both have recently expanded into European markets. A U.S. expansion also seems to be imminent.

With the entire auto industry moving towards battery powered vehicles, will the market rethink its valuation of Tesla?

Continue Reading

Subscribe

Popular